The growing number of clinics marketing stem cell therapies that are inadequately
supported by evidence of safety and efficacy is a matter of ongoing concern. Researchers
and scientific societies (notably ISCT) have worked to raise awareness and regulatory
agencies have taken action in some cases, yet the proliferation of clinics continues.
Some have suggested using consumer protection laws as another potential tool, focusing
on the claims that clinics make in marketing their services. Most jurisdictions have
laws that prohibit false or deceptive advertising, and this could provide a mechanism
by which to hold clinics accountable and prevent patients from being induced to spend
significant sums of money and put themselves at risk to try treatments that have little
or no benefit and may be harmful.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
